179487-86-6

Basic information

• Product Name: 4-[4-(ETHOXYCARBONYL)PIPERIDIN-1-YL]BENZOIC ACID
• Synonyms: 4-[4-(ETHOXYCARBONYL)PIPERIDIN-1-YL]BENZOIC ACID
• CAS NO: 179487-86-6
• Molecular Formula: C₁₅H₁₉NO₄
• Molecular Weight: 277.32
• Mol File: 179487-86-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-[4-(ETHOXYCARBONYL)PIPERIDIN-1-YL]BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(ETHOXYCARBONYL)PIPERIDIN-1-YL]BENZOIC ACID(179487-86-6)
• EPA Substance Registry System: 4-[4-(ETHOXYCARBONYL)PIPERIDIN-1-YL]BENZOIC ACID(179487-86-6)

Safety Data

• Hazardous Substances Data: 179487-86-6(Hazardous Substances Data)

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 1126-09-6 4-carbethoxypiperidine 
• 59986-44-6 benzyl 4-fluorobenzoate 
• 403-43-0 4-fluorobenzoyl chloride 
• 570408-13-8 1-{4-[(allyloxy)carbonyl]phenyl}piperidine-4-carboxylic acid ethyl ester 

Downstream Products

• 1224870-23-8 1-[4-(3-tert-butyl-phenylcarbamoyl)-phenyl]-piperidine-4-carboxylic acid ethyl ester 
• 1224870-25-0 1-[4-(1-ethyl-1H-indol-6-ylcarbamoyl)-phenyl]-piperidine-4-carboxylic acid ethyl ester 
• 1616960-80-5 ethyl 1-(4-((2-(2-methyl-1H-indol-1-yl)ethyl)carbamoyl)phenyl)piperidine-4-carboxylate 

Relevant articles and documents

Diacylglycerol Acyltransferase Inhibitors

Provided herein are compounds of the formula (I): were R1 is phenyl, R2 is hydrogen, halogen or lower alkyl, X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a 4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of triglicerides such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF

A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.

Fibrinogen receptor antagonists

This invention relates to novel compounds which inhibit platelet aggregation, pharmaceutical compositions containing the compounds, and methods of using the compounds.